What Is Elahere? Uses, Dosage, and What You Need to Know in 2026

Elahere (mirvetuximab soravtansine-gynx) is a first-of-its-kind cancer medication approved by the FDA in 2022 and granted full approval in 2024. It represents a major advance for patients with a particularly difficult-to-treat form of ovarian cancer. This article covers the basics: what Elahere is, who it's approved for, how it's given, and what patients should know going into treatment in 2026.

What Is Elahere?

Elahere is the brand name for mirvetuximab soravtansine-gynx, an antibody-drug conjugate (ADC). An ADC is a type of targeted cancer therapy that combines a monoclonal antibody (which seeks out cancer cells) with a potent chemotherapy drug (which kills those cells). This "smart bomb" design allows the chemotherapy to be delivered directly to cancer cells, reducing damage to healthy tissue.

Elahere was originally developed by ImmunoGen, Inc. and is now marketed by AbbVie, which acquired ImmunoGen in February 2024. It is the first FDA-approved ADC for platinum-resistant ovarian cancer and the first therapy in a decade to improve overall survival in this setting.

Who Is Elahere Approved For?

Elahere is FDA-approved for adult patients who meet all three of the following criteria:

FRα-positive tumor: The tumor must test positive for folate receptor alpha (FRα) expression using the VENTANA FOLR1 (FOLR-2.1) RxDx Assay.

Platinum-resistant ovarian cancer: The cancer came back or progressed within 6 months of the last platinum-based chemotherapy.

1-3 prior treatment regimens: The patient has received between one and three prior systemic treatment regimens.

This includes patients with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. About 35% of patients with high-grade serous ovarian cancer have the high FRα expression levels needed to qualify for Elahere.

What Does "Platinum-Resistant" Mean?

Platinum-based chemotherapy drugs (like carboplatin and cisplatin) are the backbone of first-line ovarian cancer treatment. When ovarian cancer comes back and stops responding to these drugs — progressing within 6 months of the last platinum dose — it's called platinum-resistant. This is one of the most challenging stages of ovarian cancer to treat, with historically low response rates (4-13%) to standard chemotherapy alone.

How Is Elahere Given?

Elahere is given as an intravenous (IV) infusion — not a pill or injection you take at home. Here's what to expect:

Dose: 6 mg/kg based on adjusted ideal body weight (AIBW), not actual body weight.

Schedule: Once every 3 weeks (Day 1 of a 21-day cycle).

Where: At an oncology infusion center, hospital infusion suite, or qualified cancer clinic.

Duration: Treatment continues until disease progression or unacceptable toxicity.

Premedication: You'll receive an antihistamine, corticosteroid, and acetaminophen about 30 minutes before each infusion to prevent reactions.

How Well Does Elahere Work?

In the pivotal Phase 3 MIRASOL trial (453 patients), Elahere significantly outperformed investigator's choice chemotherapy (paclitaxel, PLD, or topotecan):

Median overall survival: 16.5 months (Elahere) vs 12.7 months (chemo) — a 3.8-month improvement and 33% reduction in death risk (HR 0.67, p=0.0046)

Objective response rate: 42.3% vs 15.9%

Progression-free survival: 5.6 months vs 4.0 months

Elahere is the first therapy ever to improve overall survival in platinum-resistant ovarian cancer — a significant milestone for patients with limited options.

Key Things to Know Before Starting Elahere

You must have a complete eye exam before starting Elahere, and regularly during treatment — eye problems are the most common serious side effect.

Use prophylactic eye drops (provided by your oncologist) starting before your first dose.

Avoid contact lenses during treatment.

Elahere can harm an unborn baby — use effective contraception during treatment and for 7 months after your last dose.

Tell your doctor about all medications you take — especially strong CYP3A4 inhibitors like ketoconazole, itraconazole, or clarithromycin.

If you have been prescribed Elahere and need help locating an infusion center, medfinder is a paid service that calls facilities near you to find which ones can administer your prescription.

Want to understand how Elahere works at the molecular level? Read: How Does Elahere Work? Mechanism of Action Explained in Plain English.